Disc Medicine, Inc. IRON 深 沪
已收盘 02-06 16:00:00 美东时间
79.72
+1.390
+1.77%
华盛通- 最 高81.28
- 今 开79.64
- 成交量 46.31万股
- 最 低 78.75
- 昨 收 78.33
- 总市值 30.09亿
- 52周最高 99.50
- 市盈率 静 --
- 换手率 1.23%
- 52周最低 30.82
- 委 比 78.22%
- 总股本 3775.02万
- 历史最高 190.85
- 量 比 1.03
- 振 幅 3.23%
- 历史最低 11.60
- 每 手 1
- 风险率 15.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks
FDA delayed fast-track reviews for multiple drugs after safety and efficacy concerns, including adverse events and a reported patient death.
01-15 21:26
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
Disc Medicine highlighted its 2025 achievements, including bitopertin's Commissioner's National Priority Review Voucher (CNPV) and FDA NDA acceptance under accelerated approval, positive Phase 2 data for DISC-0974 in myelofibrosis anemia, and initiation of Phase 2/1b studies for DISC-3405 in polycythemia vera and sickle cell disease. For 2026, the company anticipates FDA approval decision for bitopertin, Phase 2 updates for DISC-0974 and DISC-340...
01-12 13:30
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases, announced that CEO John Quisel will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. A live webcast and archived replay of the presentation will be available on the company's investor relations website. Disc Medicine is dedicated to discover...
01-07 13:30
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $109
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $91 to $109.
2025-12-16 22:56
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
Disc Medicine'sPhase 2 RALLY-MF trial shows DISC-0974 reduces hepcidin and improves iron levels, leading to significant anemia responses. 63% of nTD patients saw ≥1 g/dL hemoglobin increase持续12周, while 71% of TD Low patients achieved transfusion independence. DISC-0974 was well-tolerated, with diarrhea and UTIs as leading mild AEs. The drug demonstrated efficacy across patient subgroups, including those on JAK inhibitors. Disc aims to advance the...
2025-12-06 13:00
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $114
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $86 to $114.
2025-11-11 00:24
Disc Medicine Q3 EPS $(1.77) Misses $(1.51) Estimate
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.51) by 16.91 percent. This is a 98.88 percent decrease over losses of $(0.89) per share from
2025-11-06 21:40
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
